Co-Authors
This is a "connection" page, showing publications co-authored by Krishnan Bhaskaran and Laurie Tomlinson.
Connection Strength
1.809
-
Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet Reg Health Eur. 2021 Jul; 6:100109.
Score: 0.236
-
Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. BMJ. 2021 03 18; 372:n628.
Score: 0.234
-
Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study. BMJ Open. 2017 Nov 16; 7(11):e018153.
Score: 0.186
-
Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017 Mar 09; 356:j791.
Score: 0.177
-
Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study. BMJ Open. 2017 01 09; 7(1):e012818.
Score: 0.175
-
Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open. 2016 12 21; 6(12):e012690.
Score: 0.174
-
Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract. 2021 11; 71(712):e806-e814.
Score: 0.061
-
Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 07 14; 374:n1592.
Score: 0.060
-
Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 05 08; 397(10286):1711-1724.
Score: 0.059
-
Identifying Care Home Residents in Electronic Health Records - An OpenSAFELY Short Data Report. Wellcome Open Res. 2021; 6:90.
Score: 0.059
-
Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill. 2021 03; 26(11).
Score: 0.058
-
Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply. Lancet Rheumatol. 2021 Mar; 3(3):e172-e173.
Score: 0.058
-
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021 07; 80(7):943-951.
Score: 0.058
-
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021 Jan; 3(1):e19-e27.
Score: 0.057
-
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020 11; 8(11):1106-1120.
Score: 0.057
-
Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 08; 584(7821):430-436.
Score: 0.056
-
Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort. PLoS Med. 2017 Nov; 14(11):e1002457.
Score: 0.046